INE338H01029
INE338H01029
CONCORD BIOTECH LIMITED
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 142.42B EUR | 133.93B EUR | 106.54B EUR | 140.85B EUR |
Enterprise Value | 134.91B EUR | 133.93B EUR | 106.44B EUR | 140.85B EUR |
Valuation Multiples | ||||
Trailing P/E | 46.9x | 49.02x | 41.05x | 82.48x |
Forward P/E | 32x | -- | -- | -- |
Price to Sales | 12.85x | 12.08x | 10.1x | 19.33x |
Price to Book | 7.06x | -- | 5.28x | -- |
EV/Revenue | 12.17x | 12.08x | 10.09x | 19.33x |
EV/EBITDA | 33.52x | 30.26x | 25.18x | 48.74x |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -- | -- | -- | -- |